Results 271 to 280 of about 181,578 (308)
Some of the next articles are maybe not open access.
Chimeric antigen receptor T-cell toxicity
Current Opinion in Pediatrics, 2019Purpose of review Chimeric antigen receptor -(CAR) T-cell therapy has become a commonly used immunotherapy originally used in the treatment of B-cell leukemias but which are now applied broadly across tumor classes. Although high rates of remission are associated with CAR T-cell therapy, toxicities associated with these novel ...
DaMarcus E, Baymon, Edward W, Boyer
openaire +2 more sources
Are All Chimeric Antigen Receptors Created Equal?
Journal of Clinical Oncology, 2015In the report accompanying this article, Kochenderfer et al discuss the efficacy of autologous T cells expressing a CD19-specific chimeric antigen receptor (CAR) in patients with relapsed diffuse large B-cell lymphoma. Although previous reports have demonstrated significant antitumor activity in low-grade B-cell malignancies and B-cell acute ...
Jae H, Park, Renier J, Brentjens
openaire +2 more sources
Advances in chimeric antigen receptor T cells
Current Opinion in Hematology, 2020Purpose of review To discuss the important advances in CAR T cell therapy over the past year, focusing on clinical results where available. Recent findings Approximately 30 years after they were first conceived of and 15 years after the first small-scale single-center clinical ...
Ofrat, Beyar-Katz, Saar, Gill
openaire +2 more sources
Development of chimeric antigen receptors for multiple myeloma
Biochemical Society Transactions, 2016Multiple myeloma (MM) is a haematologic malignancy characterized by the expansion of monoclonal plasma cells in the bone marrow. It is associated with serum or urine monoclonal protein and organ damage including renal failure, anaemia, hypercalcaemia and bone lesions. Despite recent improvements MM still remains an incurable disease.
Carolina, MartÃnez-Cingolani +1 more
openaire +2 more sources
Chasing Cancer with Chimeric Antigen Receptor Therapy
Immunotherapy, 2012Many attempts to use genetically modified T cells to halt tumor progression have been met with disappointment and significant challenges in the successful application within human patients. Porter et al., however, describe the use of genetically modified lymphocytes bearing a chimeric antigen receptor that bypasses many of the common limitations of ...
Christina D, Pham, Duane A, Mitchell
openaire +2 more sources
A closer look at chimeric antigen receptor specificity
Cytotherapy, 2014The success of chimeric antigen receptor (CAR)expressing T cells as therapy for refractory hematologic malignancies (1) has spurred ongoing efforts to extend their application toward other difficult-totreat tumors. High-grade gliomas, for example, are prime candidates.
openaire +2 more sources
Chimeric antigen receptor therapy in hematologic malignancies
JAAPAABSTRACT Chimeric antigen receptor (CAR) T-cell therapy has led to significant advances in the treatment of blood cancers such as leukemia, lymphoma, and multiple myeloma, and now shows promise for solid tumors. This type of immunotherapy can achieve high response rates in patients with hematologic malignancies, but carries serious adverse ...
Elizabeth, Brownlee +2 more
openaire +2 more sources
Technologies for chimeric antigen receptor transgene delivery
Trends in Molecular MedicineEx vivo chimeric antigen receptor (CAR) T cell therapy has achieved clinical success in hematological malignancies; yet, viral transduction risks insertional mutagenesis. Developing safe and efficient nonviral approaches for the genetic engineering of T cells and other immune cells is the key to next-generation immunotherapy for cancer and noncancerous
Yudian Xiao +6 more
openaire +2 more sources